On Tuesday, Eli Lilly got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's an important benchmark to look for when looking for the best stocks to buy and watch.
Eli Lilly is currently forming a cup without handle, with a 972.53 buy point. See if the stock can break out in heavy trade at least 40% above average.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock sports a 95 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 95% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company posted 114% EPS growth. Sales growth increased 45%, up from 20% in the prior quarter. That marks one quarter of rising revenue gains.
Eli Lilly earns the No. 1 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR and Abbott Laboratories are also among the group's highest-rated stocks.
